Anticancer Drug Development: Evaluative Architecture
文献类型：期刊论文
| 作者 | Lu, Da-Yong1; Xu, Bin3 ; Lu, Ting-Ren2
|
| 刊名 | LETTERS IN DRUG DESIGN & DISCOVERY
 |
| 出版日期 | 2024 |
| 卷号 | 21期号:5页码:836-846 |
| 关键词 | Drug development microfluidics tumor microenvironment tissue culture bio-printing drug evaluation |
| ISSN号 | 1570-1808 |
| DOI | 10.2174/1570180819666220610102444 |
| 通讯作者 | Lu, Da-Yong(ludayong@shu.edu.cn) |
| 英文摘要 | Anticancer drug development is complex and multi-factorial, demanding robust drug evaluative architecture in experimental and preclinical studies. To increase the number of drug licensing, biochemical, pharmacological, technical and economic changes (balance and integration) in evaluative systems should be focused in labs throughout the world. Despite great progress, treatment breakthroughs and drug industry need new ideas and more competitive technology (new generation of in vitro test systems). Overall, drug evaluative systems comprise anticancer drug development (medicinal chemistry and pharmacology) from initial screening to clinical validity. Its advances greatly impact the outcomes of drug production (rates of final drug licensing and efficacy of therapeutics in the clinic). In this regard, creative ideas and new techniques will change the norm and convention of drug screening and mechanic exploration in the future. This article provides multi-disciplinary approaches for experimental and preclinical anticancer drug evaluations, selections and combinations (chemistry and biomedicine). Future trends for drug evaluative systems are especially highlighted in in-depth, multilateral and multidisciplinary approaches. |
| WOS关键词 | CANCER METASTASIS ; SENSITIVITY ; THERAPY ; MICROENVIRONMENT ; HETEROGENEITY ; PLASTICITY ; FIBRINOGEN ; DIAGNOSIS |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001193859000009 |
| 出版者 | BENTHAM SCIENCE PUBL LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/310520]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Lu, Da-Yong |
| 作者单位 | 1.Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China 2.Shanghai Univ, Coll Sci, Shanghai 200444, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Lu, Da-Yong,Xu, Bin,Lu, Ting-Ren. Anticancer Drug Development: Evaluative Architecture[J]. LETTERS IN DRUG DESIGN & DISCOVERY,2024,21(5):836-846. |
| APA | Lu, Da-Yong,Xu, Bin,&Lu, Ting-Ren.(2024).Anticancer Drug Development: Evaluative Architecture.LETTERS IN DRUG DESIGN & DISCOVERY,21(5),836-846. |
| MLA | Lu, Da-Yong,et al."Anticancer Drug Development: Evaluative Architecture".LETTERS IN DRUG DESIGN & DISCOVERY 21.5(2024):836-846. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。